{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T03:39:08Z","timestamp":1789875548449,"version":"4.0.1"},"reference-count":4,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2014,6,9]],"date-time":"2014-06-09T00:00:00Z","timestamp":1402272000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Fundamemntal Clinical Pharma"],"published-print":{"date-parts":[[2015,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>To report three cases of bullous pemphigoid in patients treated with vildagliptin. Case 1: An 86\u2010year\u2010old woman presented with bullous pemphigoid after 1\u00a0month of treatment with vildagliptin and metformin. After introduction of clobetasol, the symptoms resolved although vildagliptin was continued. However, the skin lesions reappeared 3\u00a0months later. Sustained remission was achieved only after definitive withdrawal of vildagliptin. Case 2: A 79\u2010year\u2010old man presented with bullous pemphigoid after 37\u2010month treatment with gliclazide, vildagliptin and metformin. The disease at first responded to clobetasol but 3\u00a0months later the lesions reappeared. They finally regressed when the gliptin was discontinued. Case 3: A 77\u2010year\u2010old woman, treated with gliclazide and vildagliptin for 26\u00a0months, presented with bullous pemphigoid, which responded well to discontinuation of the gliptin and topical clobetasol. Gliptins are new molecules for treatment of type 2 diabetes mellitus, which have been suspected of implication in bullous pemphigoid. Such cases have been described in the literature (seven with vildagliptin and three with sitagliptin). In nine of these cases, the gliptin was associated with metformin, but the latter had never been considered responsible. The mechanism implicated in the development of bullous pemphigoid has not yet been clearly identified, but may involve a modified immune response or alteration of the antigenic properties of the epidermal basement membrane. These reports support the risk of bullous pemphigoid in patients exposed to gliptins.<\/jats:p>","DOI":"10.1111\/fcp.12083","type":"journal-article","created":{"date-parts":[[2014,5,24]],"date-time":"2014-05-24T03:43:02Z","timestamp":1400902982000},"page":"112-114","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Bullous pemphigoid induced by vildagliptin: a report of three cases"],"prefix":"10.1111","volume":"29","author":[{"given":"Johana","family":"B\u00e9n\u00e9","sequence":"first","affiliation":[{"name":"D\u00e9partement de Pharmacologie, Facult\u00e9 de M\u00e9decine Centre R\u00e9gional de PharmacoVigilance Centre Hospitalier Universitaire de Lille Universit\u00e9 de Lille 2 1, place de Verdun 59037 Lille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Jacobsoone","sequence":"additional","affiliation":[{"name":"Service de Dermatologie H\u00f4pital Huriez Centre Hospitalier Universitaire de Lille 59037 Lille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Coupe","sequence":"additional","affiliation":[{"name":"Service Pharmacie Centre Hospitalier de Valenciennes Avenue D\u00e9sadrouin 59300 Valenciennes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marine","family":"Auffret","sequence":"additional","affiliation":[{"name":"D\u00e9partement de Pharmacologie, Facult\u00e9 de M\u00e9decine Centre R\u00e9gional de PharmacoVigilance Centre Hospitalier Universitaire de Lille Universit\u00e9 de Lille 2 1, place de Verdun 59037 Lille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samy","family":"Babai","sequence":"additional","affiliation":[{"name":"Centre R\u00e9gional de PharmacoVigilance H\u00f4pital Henri Mondor Assistance Publique des H\u00f4pitaux de Paris 51, av. du Mar\u00e9chal\u2010de\u2010 Lattre\u2010de\u2010Tassigny 94010 Cr\u00e9teil France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Hillaire\u2010Buys","sequence":"additional","affiliation":[{"name":"D\u00e9partement de Pharmacologie M\u00e9dicale et Toxicologie Facult\u00e9 de M\u00e9decine et CHRU Centre R\u00e9gional de PharmacoVigilance H\u00f4pital Lapeyronie 371 avenue du Doyen Gaston Giraud 34295 Montpellier cedex 5 France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie\u2010Jos\u00e8phe","family":"Jean\u2010Pastor","sequence":"additional","affiliation":[{"name":"Centre R\u00e9gional de PharmacoVigilance H\u00f4pital Salvator Assistance Publique des H\u00f4pitaux de Marseille 270 bld Sainte Marguerite, BP51 13274 Marseille cedex 9 France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marl\u00e8ne","family":"Vonarx","sequence":"additional","affiliation":[{"name":"Service de Dermatologie Centre Hospitalier de Valenciennes Avenue D\u00e9sadrouin 59300 Valenciennes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Vermersch","sequence":"additional","affiliation":[{"name":"Service de Dermatologie Centre Hospitalier de Valenciennes Avenue D\u00e9sadrouin 59300 Valenciennes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne\u2010Fleur","family":"Tronquoy","sequence":"additional","affiliation":[{"name":"Service de Dermatologie Centre Hospitalier de Valenciennes Avenue D\u00e9sadrouin 59300 Valenciennes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Gautier","sequence":"additional","affiliation":[{"name":"D\u00e9partement de Pharmacologie, Facult\u00e9 de M\u00e9decine Centre R\u00e9gional de PharmacoVigilance Centre Hospitalier Universitaire de Lille Universit\u00e9 de Lille 2 1, place de Verdun 59037 Lille France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,6,9]]},"reference":[{"key":"e_1_2_4_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2011.04062.x"},{"key":"e_1_2_4_3_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-0804"},{"key":"e_1_2_4_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2013.1073"},{"key":"e_1_2_4_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.regpep.2006.02.007"}],"container-title":["Fundamental &amp; Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Ffcp.12083","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/fcp.12083","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T15:27:56Z","timestamp":1696346876000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/fcp.12083"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,9]]},"references-count":4,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["10.1111\/fcp.12083"],"URL":"https:\/\/doi.org\/10.1111\/fcp.12083","archive":["Portico"],"relation":{},"ISSN":["0767-3981","1472-8206"],"issn-type":[{"value":"0767-3981","type":"print"},{"value":"1472-8206","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,9]]},"assertion":[{"value":"2014-01-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-05-20","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-06-09","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}